Over the past decade, Cardiac Glycosides sales in Belgium have been experiencing a consistent decline. From a value of 1.2 million euros in 2013, sales have dropped steadily to 0.6 million euros by 2023. This trend reflects a compound annual growth rate (CAGR) of -3.04% over the past five years, highlighting a declining market. The year-on-year percentage variations demonstrate this downturn, ranging from a high drop of -14.29% in 2013 and 2020 to stagnant years like 2019-2023.
Future trends to watch for include:
• Stabilization: Forecasted data from 2024 to 2028 indicate that sales are expected to stabilize at 0.6 million euros with no growth or decline, suggesting market saturation or a plateau.
• Innovation or Regulation: Any significant developments in cardiology treatments, shifts in medical guidelines or regulatory changes could impact the market either positively or negatively.
